Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ocular Behcet's disease: procedural aspects].

L Postelmans1, C Verougstraete, L Caspers-Velu

  • 1C.H.U. Brugmann et Saint-Pierre, Université Libre de Bruxelles.

Bulletin De La Societe Belge D'Ophtalmologie
|August 7, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimodal imaging, electrophysiology and follow-up of "Dark without Pressure": Case report.

Journal francais d'ophtalmologie·2024
Same author

[Preretinal foveal neovascularization in a diabetic woman].

Journal francais d'ophtalmologie·2024
Same author

Smoking and short-term response to intravitreal anti-Vascular Endothelial Growth Factor injections in neovascular age-related macular degeneration.

Journal francais d'ophtalmologie·2023
Same author

[Value of systematic screening for depressive symptoms and Charles-Bonnet syndrome in AMD patients].

Journal francais d'ophtalmologie·2022
Same author

Multimodal imaging of atypical central serous chorioretinopathy in a patient with granulomatosis with polyangiitis.

Journal francais d'ophtalmologie·2022
Same author

Clinical Utility of <sup>18</sup>F-FDG PET/CT in the Work-up of Children with Uveitis.

Ocular immunology and inflammation·2022
Same journal

Didactic image poppers maculopathy.

Bulletin de la Societe belge d'ophtalmologie·2014
Same journal

[Marcus Gunn Syndrome. Study of 3 rare cases].

Bulletin de la Societe belge d'ophtalmologie·2014
Same journal

[Ocular manifestations of children living with HIV/AIDS in Kinshasa].

Bulletin de la Societe belge d'ophtalmologie·2014
Same journal

[Management of rhegmatogenous retinal detachment with unseen breaks: about 50 cases].

Bulletin de la Societe belge d'ophtalmologie·2014
Same journal

Long term IOP lowering efficacy of bimatoprost/timolol fixed combination: a 12 month prospective study.

Bulletin de la Societe belge d'ophtalmologie·2014
Same journal

[Palpebral pilomatricoma simulating a chalazion in a young adult].

Bulletin de la Societe belge d'ophtalmologie·2014
See all related articles

Ocular Behçet disease diagnosis is clinical, marked by recurrent eye inflammation. Treatment involves immunomodulators and immunosuppressors, prioritizing drug combinations over high doses to manage toxicity and improve prognosis.

Area of Science:

  • Ophthalmology
  • Rheumatology
  • Immunology

Context:

  • Ocular Behçet disease is a clinical diagnosis.
  • Characterized by recurrent, bilateral, non-granulomatous intraocular inflammation affecting anterior and/or posterior segments.
  • Requires management of chronic inflammation and exacerbations for improved outcomes.

Purpose:

  • To outline the diagnostic and therapeutic strategies for ocular Behçet disease.
  • To emphasize the importance of combined immunomodulatory and immunosuppressive treatments.
  • To explore potential future therapeutic advancements.

Summary:

  • Diagnosis of ocular Behçet is clinical, presenting as recurrent bilateral intraocular inflammation.
  • Treatment strategies focus on combining immunomodulators and immunosuppressors, often favoring multiple agents over increased dosages to mitigate drug toxicity.

Related Experiment Videos

  • Strict control of chronic inflammation and exacerbations is crucial for improving patient prognosis.

    • Impact:

    • Provides a clinical overview for diagnosing and managing ocular Behçet disease.
    • Highlights a strategic approach to treatment, balancing efficacy with reduced drug toxicity.
    • Suggests potential future therapeutic avenues, such as Interferon alpha, for managing this complex condition.